Xin Li

Xin li graduated from Tianjin Medical University, Tianjin, China, and started postdoctoral fellow training in June, 2022. My present project focuses on T cell immune therapy, and previous project focuses on drug resistance in multiple myeloma.

Zhiwu Jiang

Zhiwu Jiang received his PhD in Guangzhou Institutes of Biomedicine and Health, China Academy of Science where he focused on the T cell immunotherapy against tumors. He joined Lu’s lab in March 2022, working on the immunotherapy project. His research mainly focuses on the development of novel immunotherapy to treat leukemia and solid tumors by using CAR-T, identifying new cancer-specific antigens, and developing novel strategies.

Muhammad Kalim

Muhammad Kalim received his PhD in Biochemistry and Molecular Biology at Zhejiang University China where he studied development of monoclonal antibodies (mAb) and antibody drug conjugates (ADC) for cancer immunotherapy. He joined Dr. Yong Lu’s lab focusing on novel scFv sequence development and target protein identification in cancer immunotherapy. In his free time, he enjoys outdoors activities and playing cricket.

Jing Fang

Ms. Jing Fang received her Master of Science degree from Texas Southern University majoring in Chemistry, where she started her research on cancer as a graduate research assistant. Her main research focus now is on cancer adoptive T cell immunotherapy.

Xiaoxuan Wang

Xiaoxuan Wang received her PhD in Tianjin Medical University in July 2022, where she studied of molecular biology/ biochemistry and oncology. She joined Lu’s lab in Sep 2022 as a postdoctoral fellow, focusing on bioinformatics and development of novel immunotherapy of cancers by using CAR-T.

Ziyu Wang

Ziyu Wang graduated from Wake Forest University as a master’s student under the mentorship with Dr. Yong Lu. He decided to obtain extra expertise in immunotherapy by working as a research assistant. He is interested in the discovery of effective adoptive T cell therapies in treating multiple myeloma.

Pan Su

Pan Su received his PhD in Shanghai Institute of Biochemistry and Cell Biology, China Academy of Science where he focused on the regulation of autoimmune responses and autoimmune diseases, like Multiple sclerosis and Asthma. He joined the Yi lab in November 2016, working on the tumor biology project. His research mainly focuses on determining the mechanisms about the regulatory role of tumor microenvironment and tumor associated-macrophages (TAMs) during the development, progression, and drug resistance in multiple myeloma. He also focuses on the tumor immunotherapy and the regulation of anti-tumor effect of T cells in tumor microenvironment. Pan Su enjoys some outdoor activities, fishing, traveling and reading in his spare time.

Liting Wang

LLiting received her PhD degree from Shanghai Jiao Tong University in Shanghai, China and joined the lab in October 2022. She is interested in structure-based anti-metastasis drug design, screen and application, and preparation and application of nanomedicine for chemodynamic therapy and immunotherapy.